Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A…
Frontieras notes milestone moment: groundbreaking of facility based on a new industrial model built on extracting the full value of…
Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer. Cells previously regarded as passive…
For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy…
Stanford University scientists developed a molecular urine analysis that can distinguish bladder cancer patients who need immunotherapy from those already…
The global train collision avoidance system market is expected to reach $13.32 billion by 2030, growing at a compound annual…
Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner fuels, hydrogen and industrial energy…
LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora…
The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents. Rail Vision’s proprietary…
LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The…